Biopharmaceutical Giant Amgen Places Its $200 Million Media Account in Review

MEC and SSCG are incumbents

Don't miss ADWEEK House at Cannes, June 16-19. Join us as we celebrate our 45th anniversary and explore the industry's now and next. RSVP.

Amgen, the world’s largest independent biotechnology firm, has launched its first full media review in more than 14 years.

According to a person with knowledge of the matter, Ark Advisors will be managing the process in which Amgen seeks a single media agency to handle planning and buying duties for all of its brands in the U.S.

The California-based company formerly known as Applied Molecular Genetics produces a variety of medications. Its most popular products are Neulasta and Neupogen, which doctors primarily prescribe to prevent infections in patients undergoing treatment for conditions like cancer and HIV.

MEC has handled the consumer side of the business since 2003, when Amgen concluded its last review, and Omnicom’s SSCG Media promotes the company’s products to healthcare professionals.




Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in